PP553 Study On The Utilization Of Medical Resources In Patients With Malignant Tumors in China

2020 ◽  
Vol 36 (S1) ◽  
pp. 42-42
Author(s):  
Yuehua Liu ◽  
Tiantian Du ◽  
Fan Zhang ◽  
Kun Zhao
Keyword(s):  
Cancer Patients ◽  
Treatment Period ◽  
Malignant Tumors ◽  
Public Health Problem ◽  
Medical Expenditure ◽  
Utilization Efficiency ◽  
Major Public Health Problem ◽  
Medical Resource ◽  
Medical Resources ◽  
End Stage

IntroductionMalignant tumors have become a major public health problem and their treatment cost is increasing rapidly in China, but treatment aimed at healing diseases or extending patients’ life. There is little empirical research on utilization of healthcare resources of terminally ill cancer patients. In order to explore the optimal treatment decision for patients and provide information for relevant decision makers, this study analyzed the consumption status of medical resources in patients with cancer during the whole treatment period, and the current medical resource utilization efficiency in different levels of hospital for end-stage cancer patients.MethodsThis study was based on the clinical treatment and payment data of 2,536 cases of patients with lung cancer from the medical insurance database during the period of 2007 to 2014 in Hubei province. We retrospectively analyzed patients’ medical expenditure and utilization of different medical resources during their whole treatment period as well as at the end stage.ResultsThe per capita inpatient expenditures of patients under 50 years old was 193,000 CNY (27,451 USD), while that of the patients over 70 years were 80,000–90,000 CNY (11,379–12,802 USD). Secondly, the medical expenditures spent during the last 6 months of life accounted for 66.1 percent of the total expenditures. Lastly, the medical expenditure spent in tertiary hospitals accounted for 95.3 percent of the total expenditure, and the expenditure was 14,200 ± 17,030 CNY (2,019.82 ± 2,422.36 USD) per visit.ConclusionsPopulation aging is not the only factor causing the rise of medical expenditure. The unclear objectives of treatment and the reverse of medical resource allocation are also important factors to boost the growth of medical expenditure. It is necessary to improve the healthcare insurance payment system, strengthen the capacity of primary medical institutions, and develop the palliative care system in China.

scholarly journals Tissue Expression of HSP27 in Prostate Cancer Is Correlated with the Aggressivity of Cancer in the Algerien Population

2020 ◽  
Vol 4 (2) ◽  
pp. 553-553
Author(s):  
Asma Bourefis ◽  
Keyword(s):  
Prostate Cancer ◽  
Gleason Score ◽  
Malignant Tumors ◽  
Public Health Problem ◽  
Tissue Expression ◽  
Major Public Health Problem ◽  
Prostate Hyperplasia ◽  
Aggressive Cancer ◽  
Shock Proteins ◽  
Cancer Tissues

Background: Prostate Cancer (CaP) is the second most common cancer in men and a major public health problem. Clinical outcomes at diagnosis are heterogeneous and difficult to predict, so predictive and diagnostic markers are needed. Heat shock proteins (HSPs) such as HSP27 are highly regulated in several malignant tumors. Basal HSP27 levels in most human tissues are low compared to high levels in tumors. Methods: In this work, we evaluated, in subjects with CaP, the levels of expression of the HSP27 antigen in tumor tissues and its association with tumor aggressiveness. The Immunohistochemical (IHC) method was used to determine the expression of HSP27 in 58 prostate cancer tissues and 4 prostate hyperplasia (BPH). Results: Tissue levels of HSP27 were significantly higher in patients with CaP than in BPH (QSM = 153.43±0; P<0.0001). In the case of aggressive cancer (Gleason score > 7), we found a very significant increase in HSP27 protein (QSM = 169.73±84.26; P<0.0001) compared to non-aggressive cancer (Gleason score ≤ 7) (QSM = 123.92± 91.36; P<0.001). Conclusion: Overexpression of HSP27 in the tissues of patients with CaP compared to patients with BPH may be of diagnostic and/or prognostic interest and maybe a therapeutic target in patients with prostate cancer.

Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association

Circulation ◽  
2020 ◽  
Vol 142 (17) ◽  
Author(s):  
Janani Rangaswami ◽  
Vivek Bhalla ◽  
Ian H. de Boer ◽  
Alexander Staruschenko ◽  
Johanna A. Sharp ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Primary Care Physicians ◽  
Public Health Problem ◽  
Major Public Health Problem ◽  
End Stage Kidney Disease ◽  
Receptor Agonists ◽  
Scientific Statement ◽  
End Stage

Chronic kidney disease (CKD) with type 2 diabetes (T2D) is a major public health problem, resulting in significant cardiovascular and kidney adverse outcomes worldwide. Despite the widespread use of standard-of-care therapies for CKD with T2D over the past few decades, rates of progression to end-stage kidney disease remain high with no beneficial impact on its accompanying burden of cardiovascular disease. The advent of the newer classes of antihyperglycemic agents, including SGLT2 (sodium glucose cotransporter 2) inhibitors and GLP-1 (glucagon-like peptide-1) receptor agonists, has changed the landscape of therapeutic options for patients with CKD with T2D, with demonstration of significant reductions in cardiovascular adverse events and progression to end-stage kidney disease. Several potential mechanisms exist through which these beneficial effects are achieved in both drug classes, which may be independent of their antihyperglycemic effects. This scientific statement summarizes the current literature on the cardiorenal protective effects with SGLT2 inhibitors and GLP-1 receptor agonists in patients with CKD and T2D. It reviews potential mechanistic pathways that may drive these benefits and summarizes the literature on adverse effects in patients with CKD and T2D at risk for or with established cardiovascular disease. Last, it provides practical guidance on a proposed collaborative care model bridging cardiologists, nephrologists, endocrinologists, and primary care physicians to facilitate the prompt and appropriate integration of these therapeutic classes in the management of patients with T2D and CKD.

A dose-escalation, Phase I study of a depot formulation of paclitaxel administered intralesionally in end-stage cancer patients with solid malignant tumors

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 2131-2131
Author(s):  
S. J. Vukelja ◽  
W. E. Samlowski ◽  
S. P. Anthony ◽  
J. C. Arseneau ◽  
J. J. Nemunaitis ◽  
...  
Keyword(s):  
Phase I ◽  
Cancer Patients ◽  
Dose Escalation ◽  
Phase I Study ◽  
Malignant Tumors ◽  
Depot Formulation ◽  
End Stage ◽  
Solid Malignant Tumors

A dose-escalation, Phase I study of a depot formulation of paclitaxel administered intralesionally in end-stage cancer patients with solid malignant tumors

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 2131-2131 ◽  
Author(s):  
S. J. Vukelja ◽  
W. E. Samlowski ◽  
S. P. Anthony ◽  
J. C. Arseneau ◽  
J. J. Nemunaitis ◽  
...  
Keyword(s):  
Phase I ◽  
Cancer Patients ◽  
Dose Escalation ◽  
Phase I Study ◽  
Malignant Tumors ◽  
Depot Formulation ◽  
End Stage ◽  
Solid Malignant Tumors

scholarly journals P1564SLEEP QUALITY ASSESSMENT ON HÉMODIALYSIS

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Cheikh Maha ◽  
Chargui Soumaya ◽  
Ben hmida Fathi ◽  
Ben abdallah Taieb
Keyword(s):  
Sleep Disorders ◽  
Public Health Problem ◽  
Cross Sectional Study ◽  
Major Public Health Problem ◽  
Cross Sectional ◽  
Obstructive Sleep ◽  
End Stage ◽  
Adequate Management ◽  
Conventional Hemodialysis

Abstract Background and Aims sleep disorders are a major public health problem, affecting the majority of patients with end-stage chronic kidney disease. The purpose of this work is to assess the quality of sleep and identify the associated factors. Method This is a single-center cross-sectional study of 57 patients on conventional hemodialysis. Clinical screening was conducted using the Epworth Sleepiness Scale. Results The average age of the patients was 53.43 years (between 25 and 82 years), with a sex ratio of 1.08. The socio-economic level was considered bad in 70% of the cases. The main co-morbidities are hypertension in 50.8% of cases and diabetes in 24.5% of cases. The average seniority on hemodialysis was 7.47 years. 53% of patients had sleep disorders and they were insomnia in 39% of cases, daytime sleepiness in 59% of cases of which it was excessive (Epworth score&gt; 15) in 15% of cases, a syndrome restless legs in 3% of cases and obstructive sleep apnea with snoring in 13% of cases. Conclusion The prevalence of sleep disorders is higher in hemodialysis patients than in the general population, and they are associated with a non-negligible cardiovascular risk, hence the importance of early detection and adequate management, thereby improving the quality of life of these patients.

scholarly journals Current Status of Mechanical Circulatory Support: A Systematic Review

2012 ◽  
Vol 2012 ◽  
pp. 1-12 ◽  
Author(s):  
Kyriakos Spiliopoulos ◽  
Gregory Giamouzis ◽  
George Karayannis ◽  
Dimos Karangelis ◽  
Stelios Koutsias ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Transplantation ◽  
Mechanical Circulatory Support ◽  
Public Health Problem ◽  
Current Status ◽  
Circulatory Support ◽  
Major Public Health Problem ◽  
Number Of Patients ◽  
Mechanical Circulatory Support Devices ◽  
End Stage

Heart failure is a major public health problem and its management requires a significant amount of health care resources. Even with administration of the best available medical treatment, the mortality associated with the disease remains high. As therapeutical strategies for heart failure have been refined, the number of patients suffering from the disease has expanded dramatically. Although heart transplantation still represents the gold standard therapeutical approach, the implantation of mechanical circulatory support devices (MCSDs) evolved to a well-established management for this disease. The limited applicability of heart transplantation caused by a shortage of donor organs and the concurrent expand of the patient population with end-stage heart failure led to a considerable utilization of MCSDs. This paper outlines the current status of mechanical circulatory support.

scholarly journals Pain in Gynecological Cancer

2021 ◽  
Vol 5 (3) ◽  
pp. 580-598
Author(s):  
Patiyus Agustiansyah ◽  
Aidyl Fitrisyah ◽  
Sartika Nopradilova
Keyword(s):  
Cancer Patients ◽  
Pain Control ◽  
International Association ◽  
Gynecological Cancer ◽  
Public Health Problem ◽  
Major Public Health Problem ◽  
Patients With Cancer ◽  
Anticancer Treatment ◽  
Prevalence Of Pain ◽  
Experience Pain

The International Association for the Study of Pain defines pain as “unpleasant sensory and emotional experiences associated with actual or potential tissue damage.” Pain is common among patients with cancer, with the prevalence of pain being 66.4% in advanced metastatic disease or terminal, 55% during anticancer treatment, 39.3% after curative treatment, and moderate to severe pain were reported in 38.0% of all patients. Pain is one of the most common and dreaded symptoms in cancer sufferers, but the exact number of cancer patients who experience pain is difficult to determine. There are a wide variety of studies in defining pain and the tools they use to measure the complexity of this symptom. Good or complete pain control can be achieved in 80-90% of cancer patients. Nevertheless, despite major advances in pain control, cancer-related pain continues to be a major public health problem globally.

scholarly journals Pain in Gynecological Cancer

2021 ◽  
Vol 5 (6) ◽  
pp. 552-570
Author(s):  
Patiyus Agustiansyah ◽  
Aidyl Fitrisyah ◽  
Sartika Nopradilova
Keyword(s):  
Cancer Patients ◽  
Pain Control ◽  
International Association ◽  
Gynecological Cancer ◽  
Public Health Problem ◽  
Major Public Health Problem ◽  
Patients With Cancer ◽  
Anticancer Treatment ◽  
Prevalence Of Pain ◽  
Experience Pain

The International Association for the Study of Pain defines pain as “unpleasant sensory and emotional experiences associated with actual or potential tissue damage.” Pain is common among patients with cancer, with the prevalence of pain being 66.4% in advanced metastatic disease or terminal, 55% during anticancer treatment, 39.3% after curative treatment, and moderate to severe pain were reported in 38.0% of all patients. Pain is one of the most common and dreaded symptoms in cancer sufferers, but the exact number of cancer patients who experience pain is difficult to determine. There are a wide variety of studies in defining pain and the tools they use to measure the complexity of this symptom. Good or complete pain control can be achieved in 80-90% of cancer patients. Nevertheless, despite major advances in pain control, cancer-related pain continues to be a major public health problem globally.

scholarly journals Alcohol and fat promote steatohepatitis: a critical role for fat-specific protein 27/CIDEC

2016 ◽  
Vol 64 (6) ◽  
pp. 1078-1081 ◽  
Author(s):  
Suthat Liangpunsakul ◽  
Bin Gao
Keyword(s):  
Liver Disease ◽  
Molecular Mechanisms ◽  
Critical Role ◽  
Public Health Problem ◽  
Specific Protein ◽  
Major Public Health Problem ◽  
Therapeutic Benefits ◽  
New Concepts ◽  
End Stage

Alcoholic liver disease (ALD) is a major public health problem worldwide and is the leading cause of end-stage liver disease. While the ultimate control of ALD will require the prevention of alcohol abuse, better understanding of the mechanisms of alcohol-induced liver injury may lead to treatments of fatty liver, alcoholic hepatitis, and prevention or delay of occurrence of cirrhosis. The elucidation and the discovery of several new concepts in ALD pathogenesis have raised our understanding on the complex mechanisms and the potential in developing the new strategies for therapeutic benefits. In this review, we provide the most up-to-date information on the basic molecular mechanisms focusing on the role of fat-specific protein 27/CIDEC in the pathogenesis of ALD.

scholarly journals Basic study of a breast cancer epidemiology among the female patients using a regional data source: Case of Chlef region, Algeria

2021 ◽  
Author(s):  
MAAMAR BOUKABCHA
Keyword(s):  
Public Health ◽  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Registry ◽  
Health Problem ◽  
Public Health Problem ◽  
Female Breast Cancer ◽  
Major Public Health Problem ◽  
Breast Cancer Patients ◽  
Female Breast

Abstract Purpose Breast cancer is a public health problem. It impact given several, important consequences for reducing this disease. We did this study to know the situation of breast cancer and the development of cancer registry. Methods Epidemiological, statistical and computer tools are used to collect, analysis and process of the data, we used the medical records to know the data information on female breast cancer patients, by collaboration with of Bedje Sisters Public Hospitalise of Chlef (BSPHC) and the Oran Cancer Registry. Results We collected approximately 177 cases of female breast cancer, and approximately 601595 female populations during the year 2016 for Chlef region. The incidence rate is more than 29 cases of female breast cancer patients per 100000 female populations for each year. Female breast cancer patients of Chlef region is a major public health problem according to the 2016 study. Incidence rates this disease are greatly increased between 55 years and 75 years old. Conclusion Prevention, early diagnostic and different care and treatment play an important role in reducing this chronic disease in this region and why not over the worldwide?

Sign in / Sign up

Export Citation Format

Share Document